Two early trials showed the feasibility of combining chemotherapy with cART, although a relatively high percentage of patients experienced severe anemia and neurotoxicy [11] or required granulocyte colony stimulating factor (G-CSF) support while on lymphoma chemotherapy [12]. This evidence concerns the gene CSF3 and anemia (phenotype).